The Global Mesenchymal Stem Cells Market Size accounted for USD 1,715.3 Million in 2021 and is projected to achieve a market size of USD 3,412.8 Million by 2030 rising at a CAGR of 8.1% from 2022 to 2030.The growing need for stem cell based research in regenerative medicine is a primary factor that is boosting the mesenchymal stem cells market value. In addition to that, the increasing number of research & development activities to discover new application is a very popular mesenchymal stem cells market trend that is strengthening the industry growth.

Mesenchymal Stem Cells Market Report Statistics

• Global mesenchymal stem cells market revenue is estimated to reach USD 3,412.8 Million by 2030 with a CAGR of 8.1% from 2022 to 2030
• North America mesenchymal stem cells market share accounted for over 48.3% shares in 2021
• According to the World Health Organization, chronic disease prevalence grew by 57% in the year 2020 throughout the globe
• Asia-Pacific mesenchymal stem cells market growth will observe fastest CAGR from 2022 to 2030
• Based on product, rat MSCs accounted for over 43% of the overall market share in 2021
• Growing cases of chronic disorders fuels the global mesenchymal stem cells market value

Tissue or 'adult' stem cells include mesenchymal stem cells (MSCs). They are ‘multipotent,' which means they can produce more than one type of specialized cell in the body, but not all of them. MSCs are responsible for the production of the various specialized cells found in skeletal tissues. They can differentiate or specialize into cartilage cells (chondrocytes), bone cells (osteoblasts), and fat cells, for example. Each of these specialized cells has its own distinct shape, structure, and function, and each belongs to a specific tissue. Furthermore, mesenchymal stem cells were isolated for the first time from bone marrow and later from cord cells, adipose tissue, and molar cells. MSCs are smaller in size and more difficult to see in histological sections. Mesenchyme is a group of mesenchymal stem cells that are widely distributed throughout the body. Mesenchymal cells can divide into numerous specialized cells and grow in vitro or in vivo.

Global Mesenchymal Stem Cells Market Dynamics

Market Drivers

• Growing adoption of MSCs for ailments due to aging
• Rising prevalence chronic disorders
• Rapid surge in cancer incidences
• MSCs usage for stroke treatment and brain repair

Market Restraints

• High cost of mesenchymal stem cells therapy
• Lack of awareness regarding MSCs treatment

Market Opportunities

• Growing application of mesenchymal stem cells in regenerative medicine
• Increasing collaborations and partnership between key players

Mesenchymal Stem Cells Market Report Coverage

Market	Mesenchymal Stem Cells Market
Mesenchymal Stem Cells Market Size 2021	USD 1,715.3 Million
Mesenchymal Stem Cells Market Forecast 2030	USD 3,412.8 Million
Mesenchymal Stem Cells Market CAGR During 2022 - 2030	8.1%
Mesenchymal Stem Cells Market Analysis Period	2018 - 2030
Mesenchymal Stem Cells Market Base Year	2021
Mesenchymal Stem Cells Market Forecast Data	2022 - 2030
Segments Covered	By Product Type, By Application, By End-User, And By Geography
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled	Axol Bioscience, BrainStorm Cell Therapeutics Inc., Cell Applications, Inc., Celprogen, Inc., Cyagen Biosciences, Cytori Therapeutics, Inc., Merck KGaA (MilliporeSigma), Lonza AG, R&D Systems, Inc., STEMCELL Technologies Inc., Stemedica Cell Technologies, Inc., and Thermo Fisher Scientific Inc.
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Mesenchymal Stem Cells Market Dynamics

Big Calls for "Bioengineering Solutions" To Fuel the Functions of Mesenchymal Stem Cells (Mscs)

According to the American Association for the Advancement of Science report, clinical trials to date show that MSCs can be safely infused in high doses and show promising results in some clinical indications. Quality control protocols to standardize MSC product potency may help reduce the risk of clinical failure, but they are unlikely to completely resolve the problem, as MSCs' innate function is not always therapeutically sufficient for disease treatment. Simple alternative bioengineering strategies that can boost the innate function of MSCs, regardless of cryopreservation, passage number, donor and tissue source, should be investigated to maximize clinical potency while preserving ease of use. Furthermore, bioengineering can be a powerful platform for translating new insights gained from a fundamental understanding of MSC behavior following infusion into more effective therapies.

Rising Prevalence of Cancer Incidences Have Gained Significant Attention for The Global Mesenchymal Stem Cells (MSCs) Market

Tumor microenvironment interacts with tumor cells, creating an environment that can either contribute to or suppress tumor development. Among the cells that play a role in the tumor microenvironment, mesenchymal stem cells (MSCs) have been shown to be capable of orchestrating the fate of tumor cells, attracting interest in the field. MSCs have been thought to have dual-bladed effects, implying either tumorigenic or anti-tumor activity. Clinical studies, on the other hand, have revealed that MSCs have a promising potential for treating human cancer cells. Among the advantageous properties of MSCs is their natural tumor-trophic migration ability, which allows for drug delivery and, thus, targeted treatment to detach tumor and metastatic cells. Furthermore, because of their easily implemented characteristics, these cells have been the target of engineering approaches in order to obtain the desired expression of anti-angiogenic, anti-proliferative, and pro-apoptotic properties, depending on the tumor type.

MSCs Possess Clinical Effects for Stroke Treatment And Brain Repair in Patient Group Bolster the Growth Of The Global Market

According to the American Heart Association, Inc., mesenchymal stem cells (MSC) have unique properties that make them an intriguing tool for studying brain repair after ischemic stroke. They have the ability to reduce overall inflammation, thereby removing the potentially toxic environment that could be causing NSC death, as well as support NSC survival and function through the secretion of various neurotrophic factors. To date, numerous preclinical studies and clinical trials have demonstrated the efficacy of MSC therapy in stroke preclinical studies and the safety of MSC treatment in clinical trials.

Mesenchymal Stem Cells Market Segmentation

The worldwide mesenchymal stem cells market is split based on product type, application, end-user, and geography.

Mesenchymal Stem Cells Market By Product Type

• Human MSCs
• Rat MSCs
• Others

According to our mesenchymal stem cells industry analysis, the rat MSCs product type sub-segment accounted for a significant share of the market in 2021. Adult stem cell differentiation, tissue engineering, cell and gene therapy, and potential future clinical applications can all be studied using rat MSCs. Rat (SD) MSCs can be used in testing and evaluating MSCs in the host animal as the cells differentiate into mature phenotypes. Rat (SD) MSCs are a preferred animal model for transplantation studies. Moreover, the Rat AD- MSCs have growth kinetic advantages in the proliferative capacity, colony-forming unite fibroblast, and population doubling time more than that of BM-MSCs.

Mesenchymal Stem Cells Market By Application

• Cardiovascular and Myocardial Infarction
• Neurodegenerative Diseases
• Autoimmune Diseases
• Injuries
• Others (Cancer, Liver Diseases, etc.)

As per the mesenchymal stem cells market forecast, The cardiovascular and myocardial infarction application segment is expected to hold an all-time high market share for the global mesenchymal stem cells (MSCs) market. This is due to the high prevalence of stroke cases observed globally among the population base. This is one of the most important factors that contribute to segmental growth.

Mesenchymal Stem Cells Market By End-User

• Pharma/Biotech Companies
• Hospitals
• Veterinary Practices
• Academic Research & Laboratories
• Clinics

Currently, the pharma/biotech companies are enjoying a significant share in 2021 and are likely to continue its trend throughout the forecast period 2022 – 2030. This is because the mesenchymal stem cells are yet on a trial purpose, thus the product is used to experimental purpose in the pharma as well as biotech companies. The highest shares in the segment is also witnesses because of the growth in the investments for research & development activities to launch effective therapies for the treatment of chronic diseases such as cancer, Parkinson’s disease, and Alzheimer’s.

Mesenchymal Stem Cells Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Latin America

• Mexico
• Brazil
• Rest of Latin America

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

The Middle East & Africa (MEA)

• Gulf Cooperation Council (GCC)
• South Africa
• Rest of the Middle East & Africa

Mesenchymal Stem Cells Market Regional Analysis

North America Accounted For the Maximum Revenue Share In 2021

North America is expected to dominate the global market for mesenchymal stem cells (MSCs). This is due to the rapid growth of technological innovations, high disposable incomes, and well-equipped healthcare centers, all of which will contribute to the growth and development of the MSCs market. Furthermore, high R&D expenditure, the availability of advanced research facilities and skilled professionals, and government initiatives all contribute to the global market's growth.

The Asia-Pacific, on the other hand, is expected to have the fastest growing CAGR in the coming years. Asia is expected to grow rapidly in the global mesenchymal stem cell market over the next five years. China and India are expected to be the Asia-Pacific region's fastest-growing mesenchymal stem cell markets. The large pool of patients and rising government funding and support are two key driving forces for the mesenchymal stem cell market in emerging countries. Furthermore, due to increased R&D budgets in Japan, China, and India, the Asia Pacific market is expected to grow at a rapid CAGR during the forecast period.

In addition, Europe is expected to have the second largest market share in the coming years. This is due to the rapid growth of technological innovations, high disposable incomes, and well-equipped healthcare facilities, all of which will contribute to the growth and development of the MSCs market. The implantation of new mesenchymal stem cells in cancer patients is expected to boost the MSC market growth in this region.

Mesenchymal Stem Cells Market Players

Some of the key mesenchymal stem cells companies in the market are Axol Bioscience, BrainStorm Cell Therapeutics Inc., Cell Applications, Inc., Celprogen, Inc., Cyagen Biosciences, Cytori Therapeutics, Inc., Merck KGaA (MilliporeSigma), Lonza AG, R&D Systems, Inc., STEMCELL Technologies Inc., Stemedica Cell Technologies, Inc., and Thermo Fisher Scientific Inc.

TABLE OF CONTENT